Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,366 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results.
Heuser M, Palmisiano N, Mantzaris I, Mims A, DiNardo C, Silverman LR, Wang ES, Fiedler W, Baldus C, Schwind S, Pardee T, Perl AE, Cai C, Kaulfuss S, Lagkadinou E, Rentzsch C, Wagner M, Wilkinson G, Wu B, Jeffers M, Genvresse I, Krämer A. Heuser M, et al. Among authors: wagner m. Leukemia. 2020 Nov;34(11):2903-2913. doi: 10.1038/s41375-020-0996-5. Epub 2020 Jul 30. Leukemia. 2020. PMID: 32733012 Free PMC article. Clinical Trial.
Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia.
Chaturvedi A, Gupta C, Gabdoulline R, Borchert NM, Goparaju R, Kaulfuss S, Görlich K, Schottmann R, Othman B, Welzenbach J, Panknin O, Wagner M, Geffers R, Ganser A, Thol F, Jeffers M, Haegebarth A, Heuser M. Chaturvedi A, et al. Among authors: wagner m. Haematologica. 2021 Feb 1;106(2):565-573. doi: 10.3324/haematol.2019.236992. Haematologica. 2021. PMID: 32241846 Free PMC article.
Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors.
Wick A, Bähr O, Schuler M, Rohrberg K, Chawla SP, Janku F, Schiff D, Heinemann V, Narita Y, Lenz HJ, Ikeda M, Ando Y, Wick W, Steinbach JP, Burger MC, Wenger K, Lassen U, Sankhala KK, Roggia C, Genvresse I, Munhoz C, Rentzsch C, Reschke S, Langer S, Wagner M, Kaulfuss S, Cai C, Lagkadinou E, Jeffers M, Peña C, Tabatabai G. Wick A, et al. Among authors: wagner m. Clin Cancer Res. 2021 May 15;27(10):2723-2733. doi: 10.1158/1078-0432.CCR-20-4256. Epub 2021 Feb 23. Clin Cancer Res. 2021. PMID: 33622704 Clinical Trial.
Growing Gold Nanostars on 3D Hydrogel Surfaces.
Vinnacombe-Willson GA, García-Astrain C, Troncoso-Afonso L, Wagner M, Langer J, González-Callejo P, Silvio DD, Liz-Marzán LM. Vinnacombe-Willson GA, et al. Among authors: wagner m. Chem Mater. 2024 May 6;36(10):5192-5203. doi: 10.1021/acs.chemmater.4c00564. eCollection 2024 May 28. Chem Mater. 2024. PMID: 38828187 Free PMC article.
Red Wine as an Aromatase Inhibitor: A Narrative Review.
Pergolizzi J Jr, LeQuang JAK, Wagner M, Salah R, Magnusson P, Varrassi G. Pergolizzi J Jr, et al. Among authors: wagner m. Cureus. 2024 May 3;16(5):e59587. doi: 10.7759/cureus.59587. eCollection 2024 May. Cureus. 2024. PMID: 38826984 Free PMC article. Review.
Differential Psychological Treatment Effects in Patients With Late-Life Depression and a History of Childhood Maltreatment.
Müller J, Elsaesser M, Müller W, Hellmich M, Hammen M, Zehender N, Riedel-Heller S, Bewernick BH, Wagner M, Frölich L, Peters O, Dafsari FS, Domschke K, Jessen F, Hautzinger M, Schramm E. Müller J, et al. Among authors: wagner m. Am J Geriatr Psychiatry. 2024 May 17:S1064-7481(24)00335-X. doi: 10.1016/j.jagp.2024.05.006. Online ahead of print. Am J Geriatr Psychiatry. 2024. PMID: 38824050
Near-death experiences after cardiac arrest: a scoping review.
Kovoor JG, Santhosh S, Stretton B, Tan S, Gouldooz H, Moorthy S, Pietris J, Hannemann C, Yu LK, Johnson R, Reddi BA, Gupta AK, Wagner M, Page GJ, Kovoor P, Bastiampillai T, Maddocks I, Perry SW, Wong ML, Licinio J, Bacchi S. Kovoor JG, et al. Among authors: wagner m. Discov Ment Health. 2024 May 28;4(1):19. doi: 10.1007/s44192-024-00072-7. Discov Ment Health. 2024. PMID: 38806961 Free PMC article. Review.
Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriers.
Stroot IAS, Bart J, Hollema H, Jalving M, Wagner MM, Yigit R, van Doorn HC, de Hullu JA, Gaarenstroom KN, van Beurden M, van Lonkhuijzen LRCW, Slangen BFM, Zweemer RP, Gómez García EB, Ausems MGEM, Boere IA, van Hest LP, Duijkers FAM, van Asperen CJ, Schmidt MK, Wevers MR, Ruijs MWG, Devilee P, Collée JM, Hebon Investigators, de Bock GH, Mourits MJE. Stroot IAS, et al. Among authors: wagner mm. Gynecol Oncol. 2024 May 24;187:198-203. doi: 10.1016/j.ygyno.2024.05.024. Online ahead of print. Gynecol Oncol. 2024. PMID: 38795508 Free article.
6,366 results